NR3C2 and hydrops fetalis: The prognosis of outpatients with HF has significantly improved in the last 20 years, given the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs) as a standard of care for patients with HF with reduced ejection fraction (HFrEF)4,5.